Our Scientific Advisory Board (SAB) is composed of international key opinion leaders and scientists with broad expertise in drug discovery and development. The SAB plays an active role in the evaluation of in-licensing opportunities and NEOMED’s pipeline development. The SAB members meet regularly with the NEOMED team to maximize the chances of success of each potential drug in the pipeline.
John Dixon has 36 years experience in industrial Pharmaceutical Research & Development in several therapeutic areas. He was Head of Medicinal Chemistry at Fisons for 20 years, Vice President of Preclinical R&D in Astra Charnwood for 4 years and Vice President of Drug Discovery at AstraZeneca Charnwood for 9 years and in charge of 450 scientists.
During this overall period, 7 Charnwood drugs reached Phase III and he is an inventor of 2 of these. As VP of AstraZeneca Charnwood he delivered 35 candidate drugs (recently in the Respiratory & Inflammation areas, most of which were given by the inhaled route) several of which are in full clinical development. Brilinta, a blockbuster for thrombotic disorders, achieved widespread regulatory approval in 2010-2012. A second drug Cangrelor received marketing approval in Europe in February 2015 followed by FDA approval in June 2015.
A Fellow of the Royal Society of Chemistry and Member of the American Chemical Society, he served on several professional and academic advisory committees and was awarded an honorary D.Sc. from Loughborough University in 2004.
He is now Director of JD International Consulting Ltd. (www.jdinternationalconsulting.com). His consultancies cover most aspects of Drug Discovery and Early Development in most therapeutic areas.
Dr. Brown is currently a member of NEOMED’s Scientific Advisory Board and the Director of Project Pharm LLC, specializing in providing advice to pharmaceutical drug discovery and development projects. Previously, Fred was Vice president of research with AstraZeneca Pharmaceuticals. In that role he oversaw all of AstraZeneca’s late-stage, drug-discovery projects for CNS and Pain indications, as a member of a global management team responsible for 3 research sites. He was responsible for helping identify and progress promising drug candidates toward clinical evaluation.
During his 28-year tenure with AstraZeneca and its predecessor companies, Dr. Brown held a number of managerial and scientific positions. He was responsible for coordinating employee moves in a global consolidation of AstraZeneca Research. He was the founder and leader of the Project Leaders’ Network across all of AstraZeneca’s worldwide research sites. He served as the Head of the Wilmington DE Discovery organization and as Chairman of Zeneca’s Respiratory Therapy Area Team charged with plotting long-term strategy. Fred has worked in drug discovery projects for respiratory, renal, and infection indications in the US and the UK. He managed teams that nominated 4 clinical candidates, with 2 of those successfully transitioning into clinical trials. He is an inventor of Accolate, which brought to market the first novel mechanism for the treatment of asthma in several decades. Fred participated in a Pharmaceutical Manufacturers of America’s campaign to raise public awareness of the benefits of drug research by way of presentations and nationally aired TV commercials.
Fred received a Ph.D. in organic chemistry from Stanford University and completed a NIH-sponsored post-doctoral fellowship at the University of Wisconsin. He has authored 26 peer-reviewed scientific articles, has presented 12 lectures at conferences throughout the world, and is an inventor on 17 U.S. patents.
Dr. Sailaja Bhaskar was appointed Senior Director, Clinical Research and R&D Projects, at Purdue Pharma on April 18, 2016 and promoted to Executive Director, Clinical Research and R&D Projects in March 2017.
Dr. Bhaskar is responsible for building a R&D project-based organization, developing cross-functional R&D strategies, and ensuring their efficient delivery, for all our key assets. She brings to this key leadership role more than 20 years of progressive experience in leading global drug development in various therapeutic areas. In her most recent appointment as Head of Clinical Research at Noven Pharmaceuticals, she was responsible for clinical strategy, clinical development and life cycle management of multiple drugs in women’s health and CNS. She was the Global Project Lead for a schizophrenia product and US Scientific Lead for an OA product.
Dr. Bhaskar is a registered Pharmacist and earned her M.Sc. and Ph.D. in Pharmacology from Temple University, Philadelphia.
William Greenlee began his career in medicinal chemistry at Merck Research Laboratories, Rahway, NJ, where he was Senior Director, Basic Medicinal Chemistry. He later joined the Schering-Plough Research Institute, Kenilworth, NJ where has was Vice President of Chemistry, CNS and Cardiovascular/Metabolic Diseases. For the past five years, he has worked as an independent medicinal chemistry consultant, and serves on several scientific advisory boards. His career spans over 35 years, and includes contributions to the discovery of enalapril (Vasotec™), lisinopril (Prinivil™) and vorapaxar (Zontivity™). Dr. Greenlee has been the recipient of numerous honors and awards including the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society (ACS). He was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006, and was elected an ACS Fellow in 2009 and an AAAS Fellow in 2006. He is co-author of over 200 research papers, and an inventor of over 90 issued U.S. patents.
Jennifer Hamilton is the Senior Director, New Ventures at Johnson & Johnson Innovation and has worked with J&J scouting new technology opportunities in Canada since 2010.
Prior to working with Johnson & Johnson Innovation, Jennifer spent 17 years in venture capital as Venture Partner at UK-based Nomura Phase4 Ventures and an Investment Director with Rothschild Asset Management. She has also worked as an advisor to early and late-stage companies, venture funds and pension funds giving financing, business development and M&A advice. Jennifer has an MSc and a PhD in Experimental Pathology/Lipid Metabolism from the University of British Columbia and a BSc from the University of Guelph.
Dr. Kenakin’s current research interests at the University of North Carolina Medical School focus on the therapeutic exploitation of 7TM receptor functional selectivity and allosteric control of 7TM receptor signalling. In 2011, Professor Kenakin’s achievements earned him the prestigious Ariens award in Pharmacology, the Pharmacology Medal from the Norwegian Pharmacological Society and the Gaddum Award from the British Pharmacological Society.
Dr. Miller is a specialist in Clinical Pharmacology and Exploratory Medicine. In 1987, he obtained an MD at SUNY Upstate Medical College, an Internal Medicine certification at University of Rochester in 1991, and a fellowship training in Endocrinology and Clinical Pharmacology at Stanford University in 1995. He designed and supervised numerous early phase development programs in osteoporosis, obesity, diabetes mellitus, gynecological disorders and chronic kidney disease with Lilly and Pfizer. He served as Chief Medical Officer with the Chorus group at Lilly, supervising scientific staff in the conduct of fast-to-POC clinical development. He retired from Lilly in 2013 and currently consults on early phase drug development, and practices Hospital Medicine and Endocrinology.
Dr. Newbold and his group support established Worldwide Research & Development (WRD) alliances with numerous universities and biotechnology companies. The mission of the External Science & Innovation organization is to strengthen Pfizer’s access to cutting edge science at institutions in the US and Europe in alignment with the needs of Pfizer’s Research Units.
Dr. Wegner is a passionate translational scientist and strategic leader with over 25 years of academic and biopharmaceutical research experience. He has published peer-review manuscripts, review articles, edited books and led small initiatives through to large department teams spanning a number of disease areas and disciplines. Presently, Craig champions an internal Drug Repositioning Ideation Team, manages AZ’s partnership with the NIH/NCATS, and leads AstraZeneca’s expanding Open Innovation platform that partners internal assets and knowhow with the disease insight and expertise of academic physician- and basic-scientists to collaboratively advance pioneering research and therapies for the benefit of patients.
Dr. Rulleau, Ph.D is a partner at CTI Life Sciences Fund, a life sciences venture capital fund. Dr. Rulleau has served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years. As an analyst, she covered over 100 life sciences companies including scientific due diligence, market and competitive analysis. Dr. Rulleau was ranked the #1 Canadian life sciences analyst by the Starmine survey and #1 independent analyst by Brendon Wood survey. Dr. Rulleau has been involved in numerous mergers and acquisitions as well as IPOs.
Previously Dr. Rulleau was CEO of HLA-G Technologies, a biotechnology start-up based in France and also served as Vice President Business Development of Univalor, the technology transfer office of Montreal’s university and affiliated schools. Under her responsibility at Univalor completed more than 40 industry licenses and launched 8 start-up companies.
Dr. Rulleau has a Ph.D. from Université de Montréal earned at the Montreal Clinical Research Institute.
Andy Pope has nearly 30 years of experience working in drug discovery research. He gained his D.Phil. in biochemistry/biophysics at the University of York. Much of his career has been concerned with the development & application of methods to identify & refine potential new medicines through the use of biological assay technology. He played a key role in the development & deployment of miniaturized ultra-High throughput screening (uHTS) methods. Following the formation of GSK, he relocated to Philadelphia from the UK and subsequently built a number of platform based departments. These groups provided support to therapeutic targets across GSK via assay development, lead identification and compound profiling. From 2006- 2013, Andy directed GSK’s US Lead Discovery activities, including High Throughput Screening (HTS) and Encoded Library Technology (ELT) methods, as well as providing hit-to-lead and lead optimization profiling to >20 therapy units. Andy’s passion is to maximize the leverage obtained from the combination of powerful platform capabilities with new insights into disease biology to deliver new medicines and to drive new ways of doing drug discovery. Andy joined the GSK’s Discovery Partnerships with Academia (DPAc) group in 2013 and, amongst other roles, leads the Discovery Fast Track Program in North America.